tbuckley/cabot-search huggingface dataset:
Abstract 3577: A decade of changed behavior: Trends in screening adherence and incidence 2000-2010
Authors: Tainya C. Clarke, Manuel A. Ocasio, Alberto J. Caban-Martinez, David J. Lee, Kristopher L. Arheart
Journal: Cancer Research (2012)

Abstract Background: Cancer is still one of the most prominent diseases of all times claiming more than 569,490 lives in 2010. Over the past decade the United States (U.S.), like many other industrialized and developed nations have seen a significant decrease in the incidence of cancers and have experienced an increase in the number of cancer survivors. The decrease in incidence can be attributed to an increase in the number of persons adhering to recommended cancer screenings. In 2012, there will be an estimated 1 million newly diagnosed Americans, 75% of who would have adhered to recommended cancer screening in the previous year. Methods: We used incidence data from the Surveillance Epidemiology and End Results database (2000 -2008) to assess the trend in incidence rates of some of the most common cancers in the United States. Using SAS version 9.2, we pooled data from the National Health Interview Survey (NHIS) - Cancer Supplements (2000, 2005 and 2010) and analyzed adherence to recommended screening (n= 90,959). The guidelines provided by the American Cancer Society were used to guide analyses. Screening compliance was measured among the appropriate age and sex cohort within the U.S. population. Results: There has been a 17.22% decrease in the incidence of colorectal cancers and a11.06% decrease in lung cancer incidence between 2000 and 2008. While Bladder and Cervical cancer showed no significant time trends, gender specific cancers, namely prostate and breast also showed significant decreases; 16.21% and 6.78% respectively. There was an 18.12% increase in the incidence of Melanoma cases. There was a significant increase in adherence to recommended screening between 2000 and 2010. Adherence to mammography screening guidelines increased two fold between 2000 and 2010 as represented by women interviewed in the NHIS. Similar trends were observed for pap smears and colorectal screenings; 2010 analyses showed 70.48% compliance for mammography, 72.80% for colorectal screening and 68.19% for pap smears. Conclusion: Though screening compliance is below the preferred level, there has been an increase in adherence to recommended screening in the U.S. population over the past decade. This has translated into decreased cancer incidence and an increased prevalence as more persons live beyond the five year survivor mark. Identification of cancers with high incidence rates is needed to direct targeted interventions and public health campaigns. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 3577. doi:1538-7445.AM2012-3577
Abstract 3807: ER-60 increases cell migration and serves as a prognostic marker of cervical cancer
Authors: Chia-Jung Liao, Yang-Hsiang Lin, Kwang-Huei Lin
Journal: Cancer Research (2011)

Abstract Cervical cancer is the second most common cancer in women worldwide. Human papilloma virus infection is the primary cause of cervical cancer, although it cannot cause cancer by itself. Molecular markers involved in cervical carcinogenesis are needed. A two-dimensional polyacrylamide gel electrophoresis (2-DE) proteomic strategy was used to discover genes with exceptional expression from four paired cervical cancer tissues. Immunoblotting and immunohistochemical analysis with 52 paired specimens and 107 sections were used to confirm the results of 2-DE, and the clinical significance was estimated. The molecular functions of ER-60 were investigated in vitro and in vivo. We identified ER-60 was upregulated in 71.2% of cancerous tissues. ER-60 expression differed significantly between patients with different histological types and differentiation grades (P = 0.013 and 0.045, respectively). Patients with high ER-60 expression had a lower 5-year overall survival (OS) and recurrence-free survival (RFS) rate (P = 0.038 and 0.017, respectively). High ER-60 expression was an independent prognostic factor of poor RFS (P = 0.019). Knockdown of ER-60 expression in HeLa cell decreased cell motility. The lung metastasis was inhibited when introduced ER-60-knockdown cells into severe combined immunodeficiency mice. We observed accumulation of b-catenin and regulation of b-catenin downstream CD44 and S100A4 expression in ER-60-knockdown cell were responsible for this migration inhibition. Taken together, ER-60 overexpression is a potential prognostic factor of poor OS and an independent factor of poor RFS in cervical cancer. ER-60 may be involved in cervical cancer invasion by modulating b-catenin protein stability and signaling. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3807. doi:10.1158/1538-7445.AM2011-3807
OP0287 The Effectiveness of Educational Programs for Patients with Ankylosing Spondylitis in Clinical Practice
Authors: L. Myasoutova, S. Lapshina, Z. Nigmatullina
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> An effective and long-term treatment of ankylosing spondylitis (AS) is not possible without active participation of the patient in the process, which requires educational programs. <h3>Objectives</h3> To assess the effectiveness of educational activities for patients with AS. <h3>Methods</h3> Main group: 43 patients with a documented diagnosis of AS have been trained in the school of patients 5 times (3 in the first month and 2 every 2 months). The importance of regular exercises, physical therapy, continuous administration of non-steroidal anti-inflammatory drugs was discussed. Control group: 40 patients received information about disease only during a rheumatologist consultation. The groups were associated by sex, age, duration of symptoms, disease activity, medications. At baseline and after 6 months BASDAI, ASDAS, BASFI indexes, overall labor productivity according to the questionnaire WPAI, evaluated regular exercises and commitment to treatment were determined <h3>Results</h3> After 6 months of training BASDAI decreased by 2,1 ± 0,23 points in the main group and 1,4 ± 0,28 points in the control group (p &lt;0,05), BASFI at 1,7 ± 0,31 points, the main group, 0,99 ± 0,34 a control group (p &lt;0,05), ASDAS decreased by 1,74 ± 0,32 in the group trained on 1, 31 ± 0,29 in the control group (p &lt;0.05). After 6 months of improvement achieved by criteria ASAS40 - 54,5% treatment group vs. 30.0% in controls, p &lt;0.05. After 6 months, the proportion of patients who regularly perform physical exercise and / or the swimming pool, in the intervention group increased by 3.4 times and amounted to 79.1% of patients in the control group - 1.7 times and amounted to 37.5%. In the study group 74.4% of patients continually used NSAIDs, regardless of pain, in the control group 30% of patients constantly used NSAIDs, and the rest only on request. The overall decline in labor productivity (WPAI) was 30.2% at baseline, 6 months after the patient education, it was 21.7%. in the control group, WPAI was 29.4% at baseline and 25.2% after 6 months respectively. The dynamics in the group of patients who have received training was more significant that has defined significant differences between the groups in most parameters (p &lt;0.05). <h3>Conclusions</h3> Educational programs for patients increase compliance to treatment, helps to control the activity of the disease, improves functional status and performance of patients with AS. <h3>Disclosure of Interest</h3> None Declared
A phase II study of oxaliplatin, capecitabine and bevacizumab in the treatment of metastatic colorectal cancer
Authors: N. Fernando, D. Yu, M. Morse, G. Blobe, L. Odogwu, J. Crews, A. Polito, W. Honeycutt, A. Franklin, H. Hurwitz
Journal: Journal of Clinical Oncology (2005)

3556 Background: Bevacizumab (BV), a monoclonal antibody directed against vascular endothelial growth factor, provides a survival advantage when added to first line therapy for metastatic colorectal cancer. The FOLFOX regimen is superior to bolus IFL, but requires the inconvenience of an ambulatory infusion pump. We aimed to investigate the combination of capecitabine, oxaliplatin and bevacizumab (XeloxA) as a more convenient and active regimen. Methods: Patients with untreated metastatic colorectal cancer received oxaliplatin 85 mg/m 2 day 1, capecitabine 1000 mg/m 2/bid days 1–5 and 8–12, and BV 10 mg/kg day 1. Cycles were repeated every 2 weeks. The starting dose of capecitabine was changed to 850 mg/m 2/bid due to toxicity in the first 27 patients. Patient data were analyzed under an intention to treat method.. Results: Thirty patients received therapy: 16 men, 14 women, median age 55.5 (range 24–76). Diarrhea was prominent occurring at any grade in 22/30 (73%) patients, although only 9/30 (30%) had grade 3 diarrhea and no patient experienced grade 4 diarrhea. Of the three patients started at the 850 mg/m2/bid dose of capecitabine, none have experienced > grade 1 diarrhea. Hand-foot syndrome (HFS) was seen in most patients; 6/30 (20%) with grade 1, 12/30 (40%) with grade 2 and 1/30 (3%) with grade 3 HFS. Other toxicities were minimal including grade 3 neutropenia (7%), grade 3 nausea and vomiting (7%), and grade 3 peripheral neuropathy (10%). Twenty patients (66%) required at least one dose reduction of capecitabine, and 12/30 (40%) required 2 or more dose reductions during treatment, typically for diarrhea and/or HFS. There were sixteen partial responses and one complete response (RR=57%; 95% CI: 37% -75%). Eleven (37%) patients had stable disease. Median time to progression was 11.9 months (95% CI: 9.8 to ∞). Conclusions: Preliminary evidence suggests that the XeloxA regimen is highly active. The reported median time to progression is among the highest yet obtained in the first line treatment of metastatic colorectal cancer. The initial capecitabine dosing schedule was decreased due to toxicity, and thus far appears to be better tolerated. Enrollment will continue to a planned accrual of 50 patients. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Genentech, Roche Genentech
Comparison of the 5-Hydroxytryptamine<sub>3</sub>(Serotonin) Antagonist Ondansetron (Gr 38032F) with High-Dose Metoclopramide in the Control of Cisplatin-Induced Emesis
Authors: Michel Marty, Pierre Pouillart, Susy Scholl, Jean Pierre Droz, Mohamed Azab, Nils Brion, Eric Pujade-Lauraine, Bernard Paule, Dominic Paes, Jacques Bons
Journal: New England Journal of Medicine (1990)

To compare ondansetron (GR 38032F), a 5-hydroxytryptamine3-receptor antagonist, with metoclopramide in the prophylaxis of acute cisplatin-induced emesis, we conducted a double-blind crossover study in 97 patients scheduled to receive cisplatin (80 to 100 mg per square meter of body-surface area) for treatment of cancer. None had received chemotherapy before this trial.
Abstract 1184: Prognostic significance of genetic alterations detected by high-density single nucleotide polymorphism (SNP) array in gastrointestinal cancer
Authors: Motohisa Tada, Fumihiko Kanai, Yoshinari Asaoka, Yasuo Tanaka, Keisuke Tateishi, Hideaki Ijichi, Miki Ohta, Motoko Seto, Masashi Sanada, Yasuhito Nannya, Fumio Imazeki, Osamu Yokosuka, Seishi Ogawa, Masao Omata
Journal: Cancer Research (2010)

Abstract (Background and aims) We sought to identify specific gene that would be useful for predicting the prognosis of gastrointestinal cancer by the use of high-density single nucleotide polymorphism (SNP) array. (Materials and Methods) We performed genome-wide analysis of 35 colorectal cancer (CC), 34 gastric cancer (GC), 17 Liver cancer and 26 pancreatic cancer cell lines using Affymetrix GeneChip Human mapping 100K Set. These analyses showed 10 remarkably recurrent homozygous deleted regions. These 10 regions were fine and contained only 1-2 genes, respectively. So, we chose 10 genes from these 10 regions and performed loss of heterozygosity (LOH) analyses using 64 CC (38 men and 26 women; mean age; 65.8±10.4 yr) and 42 GC (29 men and 13 women; mean age; 64.8±11.7 yr) tissues. For precise evaluation of LOH, laser capture microdissection was performed, minimizing the chance of contamination by non-tumor tissues. These 10 genes included the genes that have been not reported to be deleted in cancer besides FHIT and CDKN2A gene, which were known to be deleted in several cancers. (Results) LOH of these 10 genes was detected in 35.5 %-74.6 % of CC and 39.0 %-67.5 % of GC tissues, respectively. We divided CC and GC into two groups (LOH-H; showing LOH of 5 genes or more, LOH-L; showing LOH of less than 5 genes), respectively. In CC, LOH-H showed a significant positive association with lymphatic invasion and lymph nodes metastasis (p = 0.007 and 0.04). On the other hand, LOH-H showed a significant positive association with lymph nodes metastasis (p = 0.019) in GC. The prognosis of the patients with LOH-L was significantly better than that of those with LOH-H in all CC cases (p = 0.038), while subgroup analysis showed that the prognosis of CC patients with LOH-L tended to be better than that of those with LOH-H in stage I + II CC cases (p = 0.057). Similarly, the prognosis of the patients with LOH-L was significantly better than that of those with LOH-H in all GC cases (p = 0.048). Subgroup analysis showed that the prognosis of the patients with LOH-L was also significantly better than that of those with LOH-H in stage I + II GC cases (p = 0.037). Multivariate analyses showed that stage and the LOH status were independent significant prognostic factors in CC and size and the LOH status were independent prognostic factors in GC. (Conclusion) LOH of these 10 genes might be a novel molecular signature of CC and GC with malignant phenotype. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 1184.
Hepatocellular Adenoma
Authors: DANIEL C. DAVIS, DENNIS WULFECK, MURRAY S. DONOVAN
Journal: Clinical Nuclear Medicine (1996)

An uncommon case of hepatocellular adenoma is presented. In this case, the tumor was Tc-99m SC avid rather than the typical pattern of no uptake. Liver scintigraphy was able to demonstrate that the tumor originated from the liver correlating with ultrasound and computed tomography. Background information on hepatocellular adenomas, a differential diagnosis, and a logical approach to similar liver lesions is discussed.
Cases of Malignant Lymphoma which EUS-FNA was Useful for Diagnosis
Authors: Morishima Tomomasa
Journal: Endoscopy (2011)

Background and Aims: The diagnosis of intra-abdominal lymphadenopathy is sometimes difficult, especially in patients who have no other accessible primary lesions. Malignant lymphoma is one of the main causes of this condition. Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) is a safe and accurate diagnostic procedure for lesions surrounding the gastrointestinal tract. We report patients of malignant lymphoma diagnosed by EUS-FNA in our hospital.
ESTUDIO DE LOS FACTORES DE ERROR EN LA LOCALIZACION ENDOSCOPICA DEL CANCER COLORRECTAL (CCR)
Authors: FJ Jiménez, A Borda, M Gómez, I Fernández Urién, F Borda, JM Zozaya
Journal: Endoscopy (2011)

Introduccion: La exacta localización tumoral es muy importante en el estudio pre-operatorio del CCR, especialmente para la cirugía laparoscópica, siendo variables las tasas de error de su ubicación endoscópica.
Safety Profile of Chemotherapy with Docetaxel and Cisplatin for Recurrent or Metastatic Head and Neck Cancer
Authors: T. Shimada, N. Kiyota, Y. Imamura, M. Nishimura, Y. Funakoshi, H. Tomioka, M. Toyoda, N. Chayahara, T. Mukohara, H. Minami
Journal: Annals of Oncology (2013)
A fulminant course of Cronkhite-Canada syndrome
Authors: J. Martinek, T. Chvatalova, F. Zavada, P. Vankova, I. Tuckova, M. Zavoral
Journal: Endoscopy (2010)

A 57-year-old man suffered from watery diarrhea, weight loss, and abdominal pain for 4 months. Noticeable signs of nail dystrophy (onychomadesis of all nails) were present ([Fig. 1 a]) along with alopecia and cutaneous foci of hyperpigmentation ([Fig. 1 b]).
Gastric gastrointestinal stromal tumor lost in the peritoneum after endoscopic resection
Authors: Frank Schwandner, Ernst Klar, Leif Schiffmann
Journal: Endoscopy (2014)

Submucosal tumors of the stomach are occasional findings during routine upper gastrointestinal endoscopy [1]. They may arise from any of the layers of the intestinal wall and are classified as nonepithelial or mesenchymal neoplasms [2]. The most common type is the gastrointestinal stromal tumor (GIST), first described by Mazur and Clark in 1983 [3].
PTU-233 In vivo polyp size and histology assessment at colonoscopy: are we ready to resect and discard? a multi-centre analysis of 1212 polypectomies
Authors: M F Hale, M Kurien, P Basumani, R Slater, D S Sanders, A D Hopper
Journal: Gut (2012)

<h3>Introduction</h3> The current paradigm of colonoscopic management of polyps is to resect and send for pathologic assessment. Such practice incurs substantial costs for a group of lesions with limited clinical importance. Several studies have proposed a resect and discard approach for smaller polyps. For this to be effective our in vivo assessment of polyp size needs to be accurate. Additionally a high positive predictive value (PPV) of adenomas among polyps resected is essential to ensure patients are correctly risk stratified for surveillance. <h3>Methods</h3> All polypectomies performed from 1 January 2010 to 31 December 2010 were identified retrospectively from databases in a dual site teaching hospital and local district general endoscopy units. Polyps removed and retrieved with corresponding histology were identified. Polyp site, endoscopic size and endoscopist specialty were recorded. Carcinomas, adenomas and serrated lesions were determined to be neoplastic. The total number of neoplasms removed divided by the total number of polyps removed was calculated (PPV). Fishers exact test was used to compare the subspecialties of endoscopist (nursing/surgical/medical). In vivo size was analysed for terminal digit preference by the colonoscopist compared to histology measurements using a χ<sup>2</sup> goodness of fit test. Calculations of the distribution of error between in vivo estimation and histology measurement and the number of times the size discrepancy crossed the 10 mm value used in planning surveillance colonoscopy were performed. <h3>Results</h3> 1212 polyps were included, 864 had in vivo size estimation and subsequent en-bloc histology measurements ≤20 mm. The PPV for neoplastic polyps was 69% (831/1212) with 381 non-neoplastic polyps removed. Nurse endoscopists had the highest PPV, 74% (n=347/486) compared to surgeons (PPV 72%: 143/199) and medics (PPV 64%: 339/527, p&lt;0.02). Considering proximal hyperplastic polyps as neoplastic the overall PPV=73% (879/1212), nurses PPV 75% (364/486); surgeons 74% (147/199); medical 70% (368/527); p&lt;0.1. Size assessment correlated poorly with histology with a significant increase in the use of 5 mm and 10 mm measurements in vivo (χ<sup>2</sup>=71.3 DF=9 p&lt;0.0001). 290 polyps were estimated smaller in vivo and 302 larger (294 precise) when compared to histology [distribution of error curve: SD=3.22 mm; mean=0.16 mm; median=0]. A discrepancy across the 10 mm size occurred in 96 polyps (11%). <h3>Conclusion</h3> Currently a poor PPV for neoplastic polyps and imprecise in vivo size estimation would mean a resect and discard approach would be inaccurate, but current practice removes a large amount of benign pathology and has both patient morbidity and significant cost implications. <h3>Competing interests</h3> None declared.
The Multiple Indicator Dilution Method and Its Utility in Risk Assessment
Authors: A J Schwab, K S Pang
Journal: Environmental Health Perspectives (2000)

The multiple-indicator dilution (MID) technique entails the injection of a mixture of labeled indicators into the blood vessel immediately at the entrance of an organ, e.g., the liver, kidney, heart, or lung, and characterization of outflow dilution profiles from timed venous samples. The mathematical basis of the method encompasses linear systems of partial differential equations that are formulated for flow- or barrier-limited transport combined with intracellular metabolism/excretion. The concept can be generalized to include metabolites. MID experiments are useful for determining tissue partition coefficients as well as kinetic parameters such as membrane permeabilities or metabolic/excretory intrinsic clearances, factors that affect the mean residence times or exposure of solutes to the organ. The main utility of the MID method lies in its role in identifying the basic mechanisms of the interaction of organs with vascular components. The concentration dependence in transport and removal is revealed by the rate coefficients upon varying the input concentrations of unlabeled substances into the organ at steady state. The data obtained with MID experiments can be incorporated into physiologically based pharmacokinetic (PBPK) models such as those used for biological risk assessment. This is especially pertinent in the case where diffusional barriers appear within organs. The insight gained from the MID organ approach may be useful for PBPK models with more realistic representation of organ kinetics.
Abstract 5061: Induction of B cell acute lymphoblastic leukemia by BCR/ABL requires c-Myb and its activation of Bmi-1
Authors: Todd J. Waldron, Angele R. Soliera, Ying Zhang, Robert Martinez, Terry Hyslop, Timothy Bender, Bruno Calabretta
Journal: Cancer Research (2010)

Abstract Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL), carrying the e1a2 fusion BCR/ABL oncogene, is typically an aggressive B cell leukemia, often resistant to current treatment options. The transcription factor c-Myb plays a critical role in B cell development, but its role in B cell leukemia is unknown. To study the role of c-Myb in BCR/ABL-induced lymphoblastic leukemia, we compared disease induction, latency and survival in mice expressing the BCR/ABL transgene in a c-Myb knockout versus a wild-type background. BCR/ABL+Myb+/− mice show a distinct leukemia-resistant phenotype, whereas, BCR/ABL+Myb+/+ mice exhibit rapid induction of disease with shortened survival. Using microarray analysis to examine differential gene expression, we have identified putative downstream targets of c-Myb which play a role in leukemogenesis. Subsequent use of gene overexpression, RNAi for target gene knockdown and chIP have identified the polycomb gene, Bmi-1, as a target of c-Myb transactivation. Furthermore, inhibition of the p19ARF tumor suppressor, a Bmi-1 target, may be essential to the induction of ALL by BCR/ABL. In this report, we describe the essential role that c-Myb and its activation of Bmi-1, play in BCR/ABL-induced leukemogenesis. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 5061.
Loss of Fingerprints
Authors: Yanin Chavarri-Guerra, Enrique Soto-Perez-de-Celis
Journal: New England Journal of Medicine (2015)

A 65-year-old woman with stage IV triple-negative breast cancer (a tumor characterized by the lack of estrogen and progesterone receptors and expression of human epidermal growth factor receptor type 2 [HER2]) presented after being denied authorization to perform a banking transaction because her fingerprints were unrecognizable.